CBIO FY 2021 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-88.6% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$63M-5470.7% margin

Net Income

-$63M-5469.0% margin

EPS (Diluted)

$-1.23

Cash Flow

Operating Cash Flow

-$57M

Free Cash Flow

-$58M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$94M

Total Liabilities

$13M

Stockholders' Equity

$82M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$10M	-88.6%
Gross Profit	$1M	$10M	-88.6%
Operating Income	-$63M	-$52M	-23.2%
Net Income	-$63M	-$51M	-24.3%